Which CFPS Suppliers Disclose Their Formulations and Why Most Don't

Cell-free protein synthesis reagents are a substantial market, and most of the companies selling into it will not tell a scientist what is actually in the tube. That is not a minor omission. Buffer composition, energy regeneration chemistry, and cofactor concentration determine whether a reaction folds protein correctly, and a scientist troubleshooting a failed run cannot reason about a formula that has been reduced to the word "optimized." This piece maps what CFPS suppliers actually disclose, what they withhold, and why the industry has settled on secrecy as its default setting rather than its exception.

CFPS itself is a simple idea executed with a lot of moving parts. Instead of growing protein inside a living cell, the reaction happens in a tube: a cell extract or a set of purified components supplies the transcription and translation machinery, and the scientist supplements it with the raw materials the reaction needs to run. That supplementation layer, nucleotides, amino acids, salts, an energy source, is where the real engineering lives. Academic literature is often startlingly precise about it. A published reference formulation might call for a concentrated salt solution many times the working strength with magnesium glutamate at 8 mM, ammonium glutamate at 10 mM, and potassium glutamate at 134 mM, a nucleotide mix with ATP at 1.2 mM and GTP, UTP, and CTP each at 0.85 mM, all 20 amino acids at defined concentrations, plus cofactors such as NAD and coenzyme A, polyamines, and an energy source such as phosphoenolpyruvate. That level of detail is routine in a journal's methods section. It is almost never found on a commercial product page.

Two basic architectures drive how much of that detail a supplier can even withhold. A crude lysate is a genuinely complex mixture, partially undefined by nature, since it is made by breaking open cells and keeping whatever survives the process. A reconstituted system, most notably the PURE format, is built the opposite way: every protein component is individually purified, which means the ingredient list is enumerable in principle, whether or not the vendor chooses to publish it. Extract source adds another layer of variation. E. coli extracts dominate the market, holding 47.1% share in 2024, but wheat germ, yeast (Pichia and Saccharomyces), mammalian lines like CHO, HEK, and HeLa, and rabbit reticulocyte lysate all appear on the commercial market, and each source carries its own disclosure headaches. Coupled transcription and translation held the largest application share in 2024, and that packaging choice shapes what suppliers are willing to show a customer versus what they fold into a black box labeled "reaction mix."

The commercial landscape scientists are buying from

The market is not a niche curiosity anymore. CFPS reagents were valued at a substantial sum in 2024, and Credence Research projects growth to nearly double that figure by 2032, a compound annual rate of 7.45%. North America leads with 38% share in 2024, driven largely by biotech and pharma R&D spending. That is real money attached to formulations that companies have every incentive to protect.

The supplier base splits into a few distinct groups, because reading a company's disclosure practices without knowing what kind of company it is leads to the wrong conclusion. A range of established life-science suppliers sell CFPS reagent kits through conventional catalog channels. LenioBio GmbH, which brought its ALiCE cell-free platform into North America in June 2024 through a partnership with Labscoop LLC, and Nuclera, which raised $75 million in October 2024 to commercialize its eProtein Discovery platform, operate more like platform licensors than kit vendors. Tierra Biosciences, an AI-driven CFPS company that closed an $11.4 million Series A in March 2024 led by Material Impact, is somewhere adjacent to both models. Each type of company has a different reason to disclose or withhold, and that reason usually has nothing to do with what is scientifically useful to the buyer.

The application mix explains a lot of the market's tolerance for opacity. Applications span enzyme engineering, synthetic biology, pathway prototyping, and therapeutic antibody development, among others. Industrial and pharma users buying for those purposes often care more about validated output than about compositional detail, and that tolerance is precisely what lets vendors get away with disclosing less than an academic lab would ever accept from a collaborator.

What "formulation disclosure" means in practice and how to measure it

Disclosure is not a yes-or-no question. It runs on a scale, and most commercial products land somewhere in the murky middle rather than at either end.

At the top sits full component and concentration disclosure: every ingredient named, every concentration given in exact molarity, the way an academic methods section handles it. Below that is component category disclosure, where a vendor names the classes of ingredients, ribosomes, tRNAs, an energy regeneration system, without giving concentrations or ratios. Below that again is performance disclosure only: a yield range, a size range of proteins the system can express, a list of validated targets, with zero compositional information attached. At the bottom is the true black box, where composition is withheld entirely and the extract or cell line is described in marketing language rather than technical language.

A useful audit has to look past how the product is formulated, too. Does the vendor publish lot-level QC data, or does a customer have to request it? Is the extract source strain identified by name? Is the energy regeneration chemistry, phosphoenolpyruvate, phosphocreatine, maltose, glucose, actually named? Are the supplementation add-ins, cofactors, chaperones, redox agents, listed anywhere a buyer can find them before purchase? A scientist troubleshooting a failed reaction, adapting a protocol for an unusual protein class, or validating a workflow for a regulatory submission needs different layers of that information depending on the problem, and performance specs alone solve none of it.

This is also where a common supplier tactic becomes visible in the disclosure practice itself. A company can publish an impressive yield number while withholding the exact conditions that produced it, which makes independent replication structurally impossible even when the headline data looks generous. Publishing a result is not the same as publishing a method, and the gap between the two is where most commercial disclosure actually lives.

Where meaningful disclosure exists: the PURE system and the reconstituted system advantage

The clearest example of real component-level transparency in the commercial CFPS market comes from a kit built in a defined, open-formula format, and the transparency is baked into the architecture rather than granted as a courtesy. Because every protein in a PURE system is individually purified and typically His-tagged for purification, the system cannot be built without naming what is inside it. Public documentation for this kind of product lists initiation factors (IF1, IF2, IF3), elongation factors (EF-Tu, EF-Ts, EF-G), release factors (RF1, RF2, RF3), a ribosome recycling factor, all 20 aminoacyl-tRNA synthetases, and methionyl-tRNA formyltransferase. That's not a summary; that's the actual parts list, and a buyer can look it up.

The PURE concept traces back to a reconstitution first published from a University of Tokyo lab in 2001, and commercial versions have since improved on the original kit by optimizing individual components for higher yield. What matters for the disclosure question is the mechanism, not the pedigree: a reconstituted system built from individually purified, tagged proteins is transparent almost by construction, because you cannot assemble it without knowing, and therefore being able to state, exactly what each purified protein is.

Crude lysate products, even from vendors that lean transparent on their reconstituted offerings, tell a different story. A crude-lysate kit might be described publicly as a highly active extract from a genetically engineered strain, combined with a reaction buffer and an optimized T7 RNA polymerase, capable of expressing proteins from 17 to 230 kDa. The formulation and QC details may exist inside the product manual, but the specific strain and the exact buffer recipe often stay off the public-facing page. Even a vendor that is comparatively open draws a line at the crude lysate's strain identity, which says something about where the real intellectual property sits: not in the buffer, but in the biology that makes the buffer work.

Partial disclosure and what it tells a scientist

Between full transparency and the black box sits a wide middle ground, and two examples show how differently "partial" can be defined depending on what a company chooses to protect.

Nuclera's eProtein Discovery platform describes its Core CFPS Mix as purified recombinant E. coli transcription-translation machinery containing ribosomes, tRNAs, amino acids, nucleotides, an energy regeneration system, polymerases, salts and cofactors, buffering components, and a defined redox system. That is category-level disclosure: a scientist knows the functional pieces are present and can reason about the reaction's chemistry in general terms. The platform also offers Cell-free Blends, customizable additives tailored to specific protein targets. That lets a researcher select the blend that matches a target protein's needs. What stays hidden is the precise concentration and ratio of each component, which means independent replication, or porting the recipe to a different platform, remains blocked. Nuclera's $75 million raise in October 2024 was aimed at commercializing this exact platform, and platform lock-in only works if the underlying recipe stays proprietary. Full disclosure would undercut the business model that funded the raise.

Daicel Arbor Biosciences takes a narrower approach with its myTXTL Pro Kit, an E. coli-based system built for high-yield protein synthesis. The company discloses one specific, deliberately chosen detail: the kit includes tRNAs for seven codons that E. coli rarely uses, a feature that enables expression of eukaryotic proteins the extract wouldn't otherwise handle well. That's a marketing decision as much as a technical one, since it's the differentiating feature a buyer would want to know about before purchase. The company also states publicly that its open-reaction format supports rapid, parallel production of soluble or toxic proteins, including bacteriophages. But the E. coli strain, the extract preparation method, the energy regeneration system, and the buffer composition are not published. The pattern across both companies is the same: disclose the feature that closes a sale, protect the core recipe that a competitor could copy.

The closed end of the spectrum: the XpressCF® supply-agreement model

Some CFPS technology is not sold as a kit at all, and that changes entirely what a vendor must disclose. The XpressCF platform runs on a proprietary cell-free extract drawn from a heavily engineered bacterial cell line that contains the full transcriptional and translational machinery needed to run a reaction. A customer supplies a plasmid and receives protein. The extract itself functions as a closed system by design, and there is no product page listing its contents because there is no product page to list them on.

The underlying intellectual property traces back to Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis technology. The word "open" in that name refers to the open-reaction format: the reaction isn't confined inside a cell membrane, not to any openness about formulation. That distinction means "open" describes the open-reaction format rather than any openness about formulation, so assuming it signals transparency leads to a mistaken reading of the name.

Rather than selling the extract as a reagent, this kind of platform is licensed through exclusive license agreements paired with separate exclusive supply agreements. Vaxcyte's SEC filings describe an arrangement of exactly this kind: an exclusive license, within a defined field, to develop, manufacture, or source extract and custom reagents, whether from the platform owner or from independent contract manufacturers, for vaccine production. Under that structure, the customer never prepares the extract themselves, so they never need the formulation in the first place. They are buying finished protein production capacity, not a recipe. Opacity here isn't a gap in the product; it's the business model functioning exactly as intended, and it's worth noting that the customer of record in these deals rarely asks for formulation detail, because the deal was never structured to require it.

Performance disclosure as a substitute for formulation disclosure: the wheat germ case

A commercial wheat germ system illustrates a different substitution strategy: instead of hiding behind vague marketing language, some vendors publish detailed performance data and let it stand in for compositional transparency. Sigma-Aldrich's public documentation for its wheat germ system states performance specifications including yield ranges and validation across diverse protein classes such as kinases, receptors, GPCRs, multimeric proteins, and toxic proteins, spanning a broad size range. That is a genuinely useful set of numbers for a scientist trying to decide if a system fits a given project.

What's missing is any enumeration of what's actually in the wheat germ extract. A buyer can judge fitness for purpose before ever opening a box, which is valuable, but that same buyer has no way to diagnose why a reaction failed, whether a drop in yield reflects lot-to-lot variation or a protocol mistake, or how to adjust conditions for a target the validated list doesn't cover. This is a pattern that appears across the market: application notes and lists of validated targets do a lot of the persuasive work that formulation disclosure would otherwise have to do, and in doing so, they redirect trust away from the chemistry itself and toward the vendor's own curated data.

LenioBio's ALiCE platform, a plant-based system, follows a similar structure, leaning on speed and vaccine-relevant claims, including a CEPI-funded collaboration with ReciBioPharm announced in October 2024, without confirming formulation details in public materials. Performance disclosure, in other words, is common. Formulation disclosure is rare. That gap is not an accident of how the industry happened to develop; it reflects a set of incentives that reward exactly this asymmetry.

The structural incentives that make opacity the market default

The extract and its supplementation recipe are frequently the only real differentiation between one company's CFPS product and a competitor's. Publishing the formulation means publishing the product, which is a much bigger ask than it sounds like at first.

Trade secret protection also beats patenting for this kind of asset. A patent requires public disclosure and eventually expires. A formulation kept as a trade secret requires no filing, carries no expiration date, and stays protected indefinitely, for exactly as long as the company can keep it out of a competitor's hands. Given that choice, a rational company facing no external disclosure requirement will lean on secrecy every time.

Secrecy also builds in switching costs. A scientist who cannot replicate a reaction independently cannot move to a different supplier without revalidating an entire workflow from scratch, which is expensive and slow. Publishing formulations would erase that friction, so keeping them private functions as a retention strategy whether or not any individual company frames it that way internally.

A reproducibility cost runs through all of this, and it doesn't land on the supplier. A Microbiology Society review by Aw (2026) identifies reproducibility as a persistent barrier to industrial adoption of microbial CFPS. But the scientist who can't reproduce a result absorbs that cost in wasted time and materials, not the company that sold the kit, and that misalignment removes any real incentive for suppliers to fix the problem through more transparency. Layered on top of that, no CFPS-specific quality or regulatory framework currently governs what a supplier has to document. Without an external body demanding disclosure, companies default to whatever the minimum is that still closes a sale, and right now, that minimum is set by the market's tolerance, not by any outside standard.